The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
|
|
|
- Linda Powell
- 5 years ago
- Views:
Transcription
1 NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to Title Type and code Publication date Action 1. Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32) February 3. Colon Can. Adjuvant - Capecitabine and oxaliplatin (TA100) March 4. Docetaxel in HRPC (TA101) June 5. Management of Atrial Fibrillation (CG36) June 6. Colorectal Laparoscopic surgery review (TA105) August 7. Hepatitis C Peg interferon and ribavirin (TA106) August 8. Breast (early) Trastuzumab (TA107) August
2 9. Breast cancer (early) Docetaxel (TA109) September 10. Breast cancer (early) Paclitaxel (TA108) September 11. Follicular lymphoma Rituximab (TA110) September 12. Breast (early) hormonal treatments (TA112) November 13. Gemcitabine for the treatment of early Breast ca. (TA116) January Bevacizumab and cetuximab in metastatic CRC (TA118) January Laparoscopic Radical Prostatectomy (IPG193) November 16. PDT for advanced/early oesophageal ca. (IPG200) December 18. Leukemia (Lymphocytic) Fludarabine (TA119) February MI secondary prevention (CG48) May 2007
3 21. Venous thromboembolism (CG46) April Glioma carmustine implants (TA121) July Glioma temozolomide (TA121) July Alteplase for the treatment of acute ischaemic heart disease (TA122) July Management of faecal incontinence (CG49) June Pemetrexed for the treatment of NSCLC (TA124) August Bortezomib for the treatment of multiple myeloma (TA129) October Pemetrexed for the treatment of malignant pleural mesothelioma (TA135) January Lymphoma (follicular NHL) rituximab (TA137) February Prostate cancer diagnosis and treatment (CG58) February 2008
4 31. Inadvertent peri-operative hyperthermia (CG65) April Epoetin alfa, epoetin beta and darbepoetin alfa for cancer induced anaemia (TAG142) May Cetuximab for the treatment of locally advanced SCC of H&N (TAG 145) June Erlotinib in NSCLC (TAG162) November Metastatic spinal chord compression (CG75) November Surgical site infection (CG74) October Spinal cord stimulation for chronic pain of neuropathic origin (TAG159) October Influenza (prophylaxis) amantadine, oseltamir and zanamivir (TAG158) September Medicines Adherence (CG76) January 40. Early and locally advanced Breast ca. (CG80) February
5 41. Advanced Breast ca. (CG81) February 42. Influenza zanamivir, amantadine and oseltamivir (review) (TAG168) February 43. Sunitinib for 1 st line treatment of advanced and/or metastatic RCC (TAG169) March 44. Type II Diabetes newer agents (CG87) May 45. Cetuximab in combination with FOLFOX (TAG176) June 46. Lenalidomide in MM (TAG171) June 47. Rituximab in combination with FC in 1 st line CLL (TAG174) July 48. Sunitinib in GIST (TAG179) September 49. Pemetrexed in NSCLC (TAG181) July 50. Cetuximab in H&N ca. (TAG172) August
6 51. Renal Cell Ca. (TAG178) August 52. Topotecan in recurrent stage IVb cervical ca. (TAG183) October 53. Topotecan (oral) in relapsed SCLC (TAG184) November 54. Trabectadin for treatment of advanced STS (TAG185) February 55. Venous thrombo embolism reducing the risk (CG92) February 56. Chest pain of recent onset (CG95) March 57. Unstable angina in NSTEMI (CG96) March 58. Pemetrexed maintenance (TA190) June 59. Skin Tumours including melanoma (CSGSTIM) May 60. Hepatocellular Carcinoma (advanced & metastatic) Sorafenib 1 st line (TA189) May
7 61. Imatanib for adjuvant GIST (TA196) August 62. Denosumab therapy induced bone loss in prostrate ca. July 63. Trastuzumab in GI ca. (HER2+ in combination with Cis/X or Cis/5FU) (TA208) November 64. Imatinib in GIST dose escalation 600mg or 800mg (TA209) November 65. Bevacizumab in mcrc (in combination with FOLFOX/XELOX (TA212) December 66. Sedation in children + young people for diagnostic and therapeutic procedures (CG112) December 67. Bendamustine 1 st line CLL for patients not suitable for Fludarabine (TA216) February 68. Bevacizumab in combination with a taxane for breast Ca (TA214) February 69. Azacitidine in line with licensed indication for MDS, AML, CML (TA218) March 70. Pazopanib for 1 st line Renal cell carcinoma (TA215) February
8 71. Everolimus in 2 nd line RCC (TA219) April 72. Ovarian ca. guidelines (CG122) April 73. Lung ca. guidelines (CG121) April 74. Romiplostim in chronic ITP (TA221) April 75. Erlotinib in maintenance NSCLC (TA227) June 76. Rituximab in maintenance follicular lymphoma following response to 1 st line therapy. (TA226) June 77. Rituximab as 1 st line maintenance in NHL (TA226) June 78. Bortezomib and Thalidomide as 1 st line in MM (TA228) July 79. Bivalirudin for treatment of ST segment MI (TA230) July 80. Hyperglycaemia in ACS (CG130) October
9 81. Fulvestrant in metastatic Breast ca. (TA239) December 82. Anaphylaxis (CG134) December 83. Dasatanib, high dose imatanib & nilotinib in CML (TA241) January 84. Cetuximab (in combination), Bevacizumab (in combination) and Panatumumab (monotherapy) for treatment of CRC after 1 st line chemotherapy 85. Follicular Lymphoma (stage III/IV), rituximab in combination with specific chemotherapy regimens. 86. Patient Experiences in Adult NHS Services. (TA242) (TA243) (CG138) January January February 87. Dabigatran for prevention or treatment of stroke and embolism in patients with AF (TA249) February 88. Eribulin in metastatic breast (TA250) March 89. Dasastanib, nilotinib & imatanib (standard dose) in 1 st line CML (review of (TAG70) March 90. Rivaroxaban (TA256) May
10 91. Lapataninb ad Trastuzumab in combination with an AI (TA257) June 92. Erlotinib (TA258) June 93. Rivaroxaban (TA261) July 94. Acute upper GI bleeding (CG141) June 95. VTE diseases (CG144) June 96. Bevacizumab in mbreast ca. (TA263) August 97. Neutropenic Sepsis (CG151) September 98. Denosumab (TA265) October 99. Ipilimumab in melanoma (TA268) December 100. Vemurafenib in melanoma (TA269) December
11 101. Vinflunine for urothelial tract carcinoma (TA272 ) January Bevacizumab in combination in ovarian ca Bevacizumab in ovarian, fallopian tube & primary peritoneal ca. (TA284) May 2013 (TA285) May Familial Breast Cancer (CG164) July Dapagliflozin in type II diabetes (TA288) July Ruxilitionib in Myelofibrosis (TA289) July Rivaroxaban in PE and recurrent VTE (TA287) July Myocardial infarction with ST elevation (CG167) July Eltombopag in chronic ITP (TA293) July Everolimus in combination with exemestane in advanced HER2+ve breast ca (TA295) August 2013
12 111. Crizotanib for previously treated non small cell lung cancer in associated with anaplastic lymphoma kinase infusion gene Bosutinib for previously treated chronic myeloid leukemia 113. Intravenous fluid therapy in adults in hospital (TA296) September 2013 (TA199) November 2013 (CG174) December Pixantrone in multiple relapsed (TA306) February 2014 refractory aggressive NH B cell lymphoma. Ian Chau to be made aware Clinical guideline for prostate cancer (CG 175) January Aflibercept in combination with irinotecan & 5FU (Folfiri) in mcrc following progression with oxaliplatin 117. Pemetrexed in maintenance treatment in NSCLC (TA307) March 2014 (TA309) April Afatanib in EGFR+ve locally advanced or metastatic NSCLC in TKI naïve patients 119. Bortezomib +ve. Pre high dose chemotherapy and autologous stem cell transplant. (TA310) April 2014 (TA311) April Management of atrial fibrillation (CG180) June 2014
13 121. Enzalutamide in relapsed prostrate ca. previously treated with docetaxel (TA316) July Ipilimumab in previously untreated (TA319) July 2014 advanced unresectable melanoma +ve, Melanoma unit aware of guidance and implementation date 123. Advanced breast cancer (update CG81) July Drug Allergy: Diagnosis & management of drug allergy in adults Children and Young persons Dabrafenib for the treatment of BRAF V600 mutation positive, unresectable, advanced or metastatic melanoma Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142) Sipuleucel-T. Treatment of asymptomatic/minimally symptomatic hormone relapsed prostate cancer Axitinib. Treatment of advanced RCC after failure of prior TKI s Rifaxamin. Treatment of hepatic encephalopathy. (CG183) September 2014 (TA321) October 2014 (TA323) November 2014 (TA332) February 2015 (TA333) February 2015 (TA337) March 2015
14 130. Pomalidomide Relapsed refractory myeloma previously treated with thalidomide & bortezomib Medicines Optimisation: the safe and effective use of medicines to enable best possible outcomes Apixaban for the treatment and secondary prevention of DVT and/or PE Obinutuzumab in combination with chlorambucil for untreated CLL Ofatumumab in combination with chlorambucil or bendamustine for untreated CLL Nintedanib with docetaxel, for adenocarcinoma of locally advanced, metastatic or locally recurrent NSCLC 136. Bevacizumab Relapsed platinum resistant ovarian, fallopian tube or primary peritoneal ca Edoxaban Treatment and prevention of DVT & PE Pembrolizumab in advanced melanoma after disease progression with ipilimumab (& dabrafenib, vemurafenib & trametanib in BRAF VB600+ve patients) 139. Idelalisib in combination with rituximab as a possible treatment option for : a. untreated CLL (17p deletion of (TA338) March 2015 (NG5) March 2015 (TA341) June 2015 (TA343) June 2015 (TA344) June 2015 (TA347) July 2015 (TA353) August 2015 Appraisal terminated. (TA354) August 2015 (TA357) October 2015 (TA359) October 2015
15 TP53 mutation) b. CLL previously treated but has come back within 2 years. Clinical unit leads aware nabpaclitaxel in combination with gemcitabine in previously untreated metastatic pancreatic ca Pembrolizumab for advanced melanoma not previously treated with ipilumumab 142. Trastuzumab emantansine for treating HER2 (+ve) unresectable locally advanced or metastatic Breast ca. after treatment with trastuzumab and a taxane Erlotinib and gefitinib for treating NSCLC that has progressed on prior therapy Bortezomib for previously treated mantle cell lymphoma Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. In patients with no or mild symptoms after androgen deprivation therapy has failed 146. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy, (TA360) October 2015 (TA366) November 2015 (TA371) December 2015 (TA374) December 2015 (TA370) December 2015 (TA377) January 2016 (TA381) January 2016
16 following 3 or more courses of platinum based chemotherapy 147. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) January Radium-223 dichloride for treating (TA376) January 2016 hormone-relapsed prostate cancer with bone metastases, following treatment with docetaxel 149. Ramucirumab for treating advanced gastric cancer or gastro oesophageal (TA378) January 2016 junction adenocarcinoma previously treated with chemotherapy 150. Myeloma: diagnosis and management (NG35) February Nivolumab as a treatment option for advanced resectable melanoma 152. Topotecan, pegylated liposomal doxorubicin, paclitaxel, trabectadin & gemcitabine in recurrent ovarian ca. (replacing TA91 & TA222) 153. Abiraterone in metastatic hormone relapsed prostate ca. before chemo. (TA384) February 2016 (TA389) April 2016 (TA387) April Canagliflozin, dapagliflozin & empagliflozin as monotherapies for treating type II diabetes (TA390) May Cabazitaxel in HRPC post docetaxel (TA391) May 2016
17 156. Ceritinib in previously treated anaplastic lymphoma kinase +ve NSCLC (who have previously had crizotinib) 157. Trametanib & dabrafenib unresectable or metastatic melanoma that has BRAF V600 mutation 158. Bosutinib in CML. Chronic, accelerated and blast phase (ph+ve) 159. Pemetrexed maintenance in NSNSCLC (after pemetrexed/cisplatin) 160. Ramucirumab in locally advanced NSCLC 161. Degarelix in advanced hormone dependent prostate ca (with spinal metastases) 162. Trifluidine-tipiracil in previously treated metastatic 163. Crizotinib for untreated anaplastic lymphoma kinase +ve advanced non small cell lung cancer 164. Pegasparagase for treating acute lymphoblastic leukaemia (untreated and newly diagnosed) 165. Talimogene laherparepvec in unresectable metastatic melanoma when immunotherapies are not suitable (TA395) June 2016 (TA396) June 2016 (TA401) August 2016 (TA402) August 2016 (TA403) August 2016 (TA404) August 2016 (TA405) August 2016 (TA406) September 2016 (TA408) September 2016 (TA410) September 2016
18 166. Radium 223 in hormone relapsed prostate cancer (with no known visceral metastases) 167. Necitimumab for untreated advanced or metastatic squamous NSCLC (in combination with gemcitabine & cisplatin) Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutationpositive melanoma 169. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (via CDF) 170. Nivolumab in advanced renal cell carcinoma (+ve) Everolimus with examestane fro advanced breast ca Crizotinib for previously treated anaphylactic lymphokinase 173. Eribulin fro locally advanced or metastatic breast ca Pertuzumab in neoadjuvant HER2+ve Breast ca Dasatinib, nilotinib & HD imatinib in resistant/intolerant CML (TA412) September 2016 (TA411) September 2016 (TA414) October 2016 (TA416) October 2016 (TA417) November 2106 (TA421) December 2016 (TA422) December 2016 (TA423) December 2016 (TA424) December 2016 (TA425) December 2016
19 176. Dasatinib, nilotinib & imatinib in untreated CML 177. Pomalidommide in MM previously trrated with lenalidomide & bortezomib 178. Pembrolizumab fro PDL1 +ve NSCLC (after chemotherapy) (TA426) December 2016 (TA427) January 2017 (TA428) January Ibrutinib in previously treated CLL. (TA429) January Everolimus for advanced RCC (after previous treatment). James Larkin aware of guidance Cetuximab & panitumumab for previously untreated mcrc (RAS wild type) in combination with FOLFOX/FOLFIRI 182. Nanoliposomal irinotecan for pancreatic ca. after gemcitabine (metastatic adeno ca.) (TA432) February 2017 (TA439) March 2017 (TA440) April Brentuximab for treating CD30+ve (TA446) June Pembrolizumab for untreated PDL1 +ve metastatic NSCLC (TA447) June Blinatumumab in Ph+ve ALL (TA450) June 2017
20 186. Ponatinib in CML & ALL (TA451) June Carfilzomib for previously treated MM (TA457) July Trastuzumab emtansine for HER2+ advanced Breast ca. (TA458) July Nivolumab in relapsed/refractory HL TA462 July Cabozantanib in advanced RCC (post VEGF therapy) 191. Olaratumumab in combination with doxorubicin in STS 192. Obinutuzumab plus bendamustine in follicular lymphoma 193. Cetuximab in recurrent metastatic squamous cell ca Pemetrexed maintenance in advanced NSCLC 195. Sorafenib in advanced hepatocellular ca. TA463 August 2017 TA465 August 2017 TA472 August 2017 TA473 August 2017 TA190 August 2017 TA474 September 2017
21 196. Abraxane plus gemcitabine in untreated metastatic pancreatic ca. TA476 September Relapsed refractory systematic anaplastic large cell lymphoma (ECOG 0-1) TA 478 October Nivolumab in previously treated NSCLC TA483 November Venetoclax in CLL TA487 November Regorafenib in previously treated or unresectable GIST TA488 November Vismodogib in basal cell carcinoma TA489 November Ibrutinib in Waldenstroms Macroglobulinaemia 203. Atezolizumab in untreated locally advanced or metastatic urothelial cancer 204. Palbociclib with an AI for previously untreated HR+ve, HER-ve, locally advanced/metastatic Breast ca Ribociclib with an AI for previously untreated HR+ve, HER-ve, locally advanced/metastatic Breast ca. TA491 November 2017 TA492 December 2017 TA495 January 2018 TA496 January 2018
22 206. Lenvatinib with everolimus for previously treated advanced renal cell carcinoma 207. Ceritinib for untreated ALK-positive advanced non-small-cell lung cancer 208. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer 209. Ibrutinib for treating relapsed or refractory mantle cell lymphoma only if they have had only 1 previous line of therapy 210. Fulvestrant for untreated locally advanced or metastatic oestrogenreceptor positive breast cancer 211. Ixazomib with lenalidomide and dexamethasone for treating Relapsed Refractory Multiple Myeloma Pertuzumab & Trastuzumab & Docetaxel in HER2+ve Breast ca Daratumumab (monotherapy) relapsed refractory Multiple Myeloma 214. Tivozanib for treating advanced RCC (no prior treatments) TA498 February 2018 TA500 February 2018 TA501 February 2018 Not used at the trust TA502 February 2018 TA503 February 2018 TA505 February 2018 TA509 March 2018 TA510 March 2018 TA512 March 2018
23 215. Obinotuzumab for untreated advanced follicular lymphoma (FLIPI score of 2 or more) 216. Regorafenib for previously treated advanced hepatocellular carcinoma 217. Eribulin in locally advanced breast ca (replacing TA250) 218. Cabozantanib for treating progressive medullary thyroid cancer (unresectable, advanced or metastatic 219. Avelumab for treating metastatic merkel cell carcinoma following 1 or more lines of chemotherapy 220. Pembrolizumab for locally advanced or metastatic urothelial carcinoma after platinum containing chemotherapy 221. Atezolizumab for treating locally advanced or metastatic NSCLC post chemo or EGFR/ALK +ve 222. Pembrolizumab in untreated locally advanced or metastatic urothelial ca. when cisplatin is unsuitable 223. Midostaurin in newly diagnosed FLT3+ve myeloid leukemia TA513 March 2018 TA514 March 2018 TA515 March 2018 TA516 March 2018 TA517 April 2018 TA518 April 2018 TA520 May 2018 TA522 June 2018 TA523 June 2018
24 224. Brentuximab for CD30+ve Hodgkin Lymphoma (relapsed/refractory) (TA524) 225. Atezolizumab for treating locally advanced or metastatic urothelial carcinoma 226. Arsenic trioxide in APL (including remission and consolidation) 227. Niraparib for maintenance treatment of relapsed platinum sensitive ovarian, fallopian tube and peritoneal ca Crizotinib for treating ROS1 +ve advanced NSCLC 229. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum containing chemotherapy 230. Pembrolizumab for untreated PDL1 +ve metastatic NSCLC June 2018 TA525 June 2018 TA526 June 2018 TA528 July 2018 TA529 July 2018 TA530 July 2018 TA531 July 2018
The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.
NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust
NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir
Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
Cancer drug approvals for paediatric indications (n=43)
Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December
National Cancer Drugs Fund List Ver4.4
National Cancer Drugs Fund List Ver4.4 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
National Cancer Drugs Fund List Ver4.0
National Cancer Drugs Fund List Ver4.0 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Contro VersDate Revision summary Ver 19 Mar 201 Update following Mar-14
MEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
National Cancer Drugs Fund List Ver2.1
National Cancer Drugs Fund List Ver2.1 Version Control Author(s) Owner David Thomson Chemotherapy Clinical Reference Group Version Control Version Date Revision summary Ver1.0 19 Mar 2014 Update following
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
CLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
NICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
Targeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
Molecular Profiling METASTATIC, REFRACTORY, HER2+, BREAST PHASE 1, METASTATIC, RELAPSED/REFRACTORY, PROSTATE OVARIAN
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMTN AT 513-751- 2273, EXT 27110 Phase 1 REFMAL 381 (Phase 1 open at BAM only)
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
THE DUDLEY GROUP NHS FOUNDATION TRUST FOI
THE DUDLEY GROUP NHS FOUNDATION TRUST FOI 011324 Question 2 Response shown in table below Question 4 - Please provide details of the number of applications for treatments used outside of their licensed
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
Working Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
Cancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
National Cancer Drugs Fund List
National Cancer s Fund List (Including list of NICE approved and baseline funded drugs/indications from 1st April 2016 with criteria for use) ver1.95 20-Jul-18 NHS England INFORMATION READER BOX Directorate
2014 Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee
NICE Technology Appraisals - Time to Implementation Report - 18 December 2014 Produced by Tracy Steadman, Croydon Public Health Intelligence Team (C-PHIT), Croydon Council Date of Guidance Title of Guidance
Summary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
NICE TA Adherence Check list April Drug Indication NICE Approval Release Date
NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide
Our Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
NEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria
NEW DRUG FUNDING PROGRAM (NDFP) & EVIDENCE BUILDING PROGRAM (EBP) Approved Drugs and Eligibility Criteria The information in this document is a summary of the funding criteria for the New Drug Funding
Oral Chemotherapy Agents
Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -
ORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Title Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
ORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
OPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Studienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
MEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation
NICE Technology Appraisals - Time to Implementation Report - 3 rd August 2015 Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council Date of Guidance Title of Guidance Summary
Date of HRA. Date Site Invited. Date Site Selected. Approval. Recruited. Date
14/LO/0259 134883 RE-AKT: A randomised Phase II study of enzalutamide (MDV3100) in combination with AZD5363 in s with Metastatic Castration - Resistant Prostate Cancer Yes 08/01/2018 01/07/2016 01/07/2017
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
Etudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
Keytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
8. Malignant disease and immunosuppression
1 8. Malignant disease and immunosuppression An ever increasing number of cytotoxic drugs and biological therapies - now referred to as Systemic anticancer therapy (SACT) - are used in the management of
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
Immunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
Date Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed
Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval
Global Oncology Trends 2017
June 2017 Global Oncology Trends 2017 Advances, Complexity and Cost $ Introduction Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine
Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
Open Trials as of end of March 2016
EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG
Studies proceeding under pre HRA-Approval system (NHS Permission)
15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL
New Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
European consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
CancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal
Phase 1 HEMATOLOGY. GI- 219: BBI (pending 1 st Qtr) Phase Ib Therapeutic BBI608 provided
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS, PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTMENT AT 1-800- 710-4674 Phase 1 GI- 219: BBI608-246 (pending 1 st Qtr) Phase
Index. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
Roche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
New Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
North of Tyne & Gateshead Area Prescribing Committee DECISION SUMMAY North of Tyne & Gateshead Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting
General Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 34 th Prioritization 1 st quarter 2018 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Please note: Within this document
Phase 1 HEMATOLOGY METASTATIC, REFRACTORY, HER2+, BREAST. REFMAL 381 (Phase 1 open at BAM only) Phase I Therapeutic Nivolumab and abraxane provided
FOR MORE INFORMATION OR TO REFER A PATIENT TO ANY OF OUR CLINICAL TRIALS PLEASE CONTACT NICOLE GIVEN, BS, OHC RESEARCH DEPARTEMENT AT 1-800- 710-4674 Phase 1 REFMAL 381 (Phase 1 open at BAM only) Phase
SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
Etudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination
HRA Approval Date Site Date Site Sponsor. Non- Confirmation Status. Date Site Ready To Start
Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial Date of Receipt of Date of Valid Research Application First Patient Recruited? Date
Summary of Main Points from the Meeting held on Monday 13 th February 2017
Summary of Main Points from the Meeting held on Monday 13 th February 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the December 2016 Medicines Group meeting were
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
Opdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
Haematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
Clinical Trials OPEN to ENROLLMENT
CNS 2014 Second Quarter Clinical Trials OPEN to ENROLLMENT GAB 101 (CNS THERAPEUTICS INC): Safety of 3 mg/ml Gablofen (baclofen injection) Delivered by Intrathecal Administration Using the Synchromed II
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS
CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship
CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding